Search

Your search keyword '"Mandelli F"' showing total 2,199 results
Start Over Author "Mandelli F"
2,199 results on '"Mandelli F"'

151. Acute promyelocytic leukemia: Clinical and morphologic features and prognostic factors

Author

Avvisati, G, LO COCO, F, and Mandelli, F

Subjects
Promyelocytic, Leukemia, Leukemia, Promyelocytic, Acute, Humans, Antineoplastic Agents, Prognosis, Tretinoin, Hematology, Acute, Settore MED/15 - Malattie del Sangue
Abstract

The most impressive clinical feature of acute promyelocytic leukemia (APL) at diagnosis is the presence in 80% to 90% of patients of a severe hemorrhagic syndrome. Recent data favor a fibrinolytic/proteolytic process rather than a disseminated intravascular coagulation as the mechanism mainly responsible for the hemorrhagic diathesis in APL. Morphologically, two main cytologic variants have been Identified: the classical hypergranular APL (M3), which represents the great majority of all APL, and the microgranular variant (M3v), which accounts for about 15% to 20% of all APL. A rare basophilic variant has also been described. With regard to prognosis, it has markedly changed from that of a rapidly fatal acute leukemia to that of a highly curable disease. This revolutionary progress was mainly due to the introduction during the 1990s of all-trans retinoic acid (ATRA) for the treatment of this disease. After the introduction of ATRA, in addition to clinical features such as hyperleukocytosis (white blood cell count10 x 10(9)/L) or thrombocytopenia (platelet count10 x 10(3)/L) at presentation, immunophenotype markers and polymerase chain reaction status for promyelocytic leukemia/retinoic acid receptor-alpha during follow-up also had an impact on prognosis.

Published
2001

152. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

Author

Lo Coco, F, Cimino, G, Breccia, M, Noguera, N, Diverio, D, Finolezzi, E, Pogliani, E, Di Bona, E, Micalizzi, C, Kropp, M, Venditti, A, Tafuri, A, Mandelli, F, Noguera, NI, Mandelli, F., POGLIANI, ENRICO MARIA, Lo Coco, F, Cimino, G, Breccia, M, Noguera, N, Diverio, D, Finolezzi, E, Pogliani, E, Di Bona, E, Micalizzi, C, Kropp, M, Venditti, A, Tafuri, A, Mandelli, F, Noguera, NI, Mandelli, F., and POGLIANI, ENRICO MARIA

Abstract

The anti-CD33 antibody calicheamicinconjugate gemtuzumab ozogamicin (GO) was used to treat 16 patients with acute promyelocytic leukemia (APL) who had relapsed at the molecular level. Of these patients, 8 were experiencing a first, 5 a second, 2 a third, and 1 a fourth relapse. GO was administered at 6 mg/m2 for 2 doses, and patients achieving a new molecular remission (MR) (ie, negativity of the reverse transcriptase-polymerase chain reaction [RT-PCR] test for PML/RARalpha) received a third dose. MR was obtained in 9 (91%) of 11 patients tested after 2 doses and in 13 (100%) of 13 patients tested after the third dose. Of the 3 remaining patients, 1 achieved MR after one GO administration and received no further therapy owing to hepatic toxicity, and 2 showed disease progression during treatment. Quantitative RT-PCR studies showed that responding patients experienced a dramatic decline (at least 2 logs) of the PML/RARalpha transcript after the first GO dose. Of 14 responders, 7 remained in sustained MR for a median of 15 months (range, 7-31 months) while 7 experienced relapse at 3 to 15 months. GO was administered again in 2 patients with relapse, and both obtained a new MR. These data indicate that GO is highly effective as a single treatment for patients with molecularly relapsed APL including those with very advanced disease.

Published
2004

153. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients mwithout additional chemotherapy: results of the GIMEMA LAL0201-B protocol

Author

Vignetti M, Fazi P, Cimino G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege Cambrin G, Elia L, Bertieri R, Annino L, Foa R, Mandelli F., MARTINELLI, GIOVANNI, BACCARANI, MICHELE, Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Foa R, Baccarani M, and Mandelli F.

Published
2007

154. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

Author

Testi, A, Del Giudice, I, Arcese, W, Moleti, M, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Aricò, M, Casale, F, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, M, Santoro, N, Valsecchi, M, Masera, G, Mandelli, F, Testi, AM, Moleti, ML, BIONDI, ANDREA, Pinta, MF, Mandelli, F., VALSECCHI, MARIA GRAZIA, Testi, A, Del Giudice, I, Arcese, W, Moleti, M, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Aricò, M, Casale, F, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, M, Santoro, N, Valsecchi, M, Masera, G, Mandelli, F, Testi, AM, Moleti, ML, BIONDI, ANDREA, Pinta, MF, Mandelli, F., and VALSECCHI, MARIA GRAZIA

Abstract

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complete remission; eight (8%) died during induction and 11 (11%) failed to respond. A total of 42 out of the 80 responders (52.5%) received a SCT: 19 from an identical sibling, 11 from a matched unrelated donor and 12 from umbilical cord blood cells. The estimated 4-year overall survival and event-free survival were 25% and 21% respectively. Disease-free survival at 4 years was 25.8% for the 80 responders. At 4 years, 39 out of 100 children remain alive, with 27 of them free of leukaemia. This induction therapy has shown antileukaemic efficacy with acceptable toxicity; moreover, all responders proved eligible for intensive consolidation

Published
2002

155. Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A Study of the Leukemia Cooperative Group of the EORTC and GIMEMA. European Organization for Research and Treatment of Cancer (EORTC) Leukemia Cooperative Group and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA)

Author

Keating, S., Witte, T.J.M. de, Suciu, S., Mandelli, F., Damasio, E., Willemze, R., Morra, E., Amadori, S., Dardenne, M., Vegna, M.L., and Zittoun, R.

Subjects
Hematopoiesis and stem cell transplantation
Abstract

Item does not contain fulltext In the AML 8A study patients were treated with remission-induction therapy followed by one consolidation course. Patients in complete remission (CR) were randomised between autologous bone marrow transplantation (ABMT) and a second intensive consolidation course, except for those with a histocompatible sibling donor, who received allogeneic bone marrow transplantation (alloBMT). This analysis was performed to determine whether centres which only performed induction and consolidation therapy, achieved similar results as centres who also performed transplantation. 542/676 (80%) from transplantation centres and 150/194 (77%) from referring centres achieved CR, with an early death rate of 5% and 11%, respectively (P = 0.01). 66% of patients with a donor from transplantation centres received alloBMT in first CR compared with 57% from referring centres (P = 0.2). Transplantation centres randomised 64% of patients without a donor, referring centres 47% (P = 0.04). The full protocol treatment was completed by 275/542 (51%) and 61/150 (41%) patients, respectively (P = 0.04). The overall survival rate at 6 years from diagnosis was 34% and 36%, respectively (P = 0.9). In conclusion, the type of centre did not appear to have an influence on overall survival. The feasibility of the study was acceptable for both types of centres. The referring centres applied more selection for transplantation. Despite a more intensive second-line treatment at transplantation centres, the overall outcome remained similar to that of referring centres.

Published
1999

156. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study

Author

Chiaretti, S., primary, Vitale, A., additional, Vignetti, M., additional, Piciocchi, A., additional, Fazi, P., additional, Elia, L., additional, Falini, B., additional, Ronco, F., additional, Ferrara, F., additional, De Fabritiis, P., additional, Luppi, M., additional, La Nasa, G., additional, Tedeschi, A., additional, Califano, C., additional, Fanin, R., additional, Dore, F., additional, Mandelli, F., additional, Meloni, G., additional, and Foa, R., additional

Published
2016
Full Text
View/download PDF

158. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT

Author

Hengeveld, M.M., Suciu, S., Chelgoum, Y., Marie, J.P., Muus, P., Lefrere, F., Mandelli, F., Pane, F., Amadori, S., Fioritoni, G., Labar, B., Baron, F., Cermak, J., Bourhis, J.H., Storti, G., Fazi, P., Hagemeijer, A., Vignetti, M., Willemze, R., Witte, T.J. de, Hengeveld, M.M., Suciu, S., Chelgoum, Y., Marie, J.P., Muus, P., Lefrere, F., Mandelli, F., Pane, F., Amadori, S., Fioritoni, G., Labar, B., Baron, F., Cermak, J., Bourhis, J.H., Storti, G., Fazi, P., Hagemeijer, A., Vignetti, M., Willemze, R., and Witte, T.J. de

Abstract

Item does not contain fulltext, The faster hematopoietic recovery after autologous peripheral blood SCT (APBSCT) in patients with AML may be offset by an increased relapse risk as compared with autologous BMT (ABMT). The EORTC and GIMEMA Leukemia Groups conducted a trial (AML-10) in which they compared, as second randomization, APBSCT and ABMT in first CR patients without an HLA compatible donor. A total of 292 patients were randomized. The 5-year DFS rate was 41% in the APBSCT arm and 46% in the ABMT arm with a hazard ratio (HR) of 1.17; 95% confidence interval=0.85-1.59; P=0.34. The 5-year cumulative relapse incidence was 56% vs 49% (P=0.26), and the 5-year OS 50% and 55% (P=0.6) in the APBSCT and ABMT groups, respectively. APBSCT was associated with significantly faster recovery of neutrophils and platelets, shorter duration of hospitalization, reduced need of transfusion packed RBC and less days of intravenous antibiotics. In both treatment groups, higher numbers of mobilized CD34+ cells were associated with a significantly higher relapse risk irrespective of the treatment given after the mobilization. Randomization between APBSCT and ABMT did not result in significantly different outcomes in terms of DFS, OS and relapse incidence.

Published
2015

159. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

Author

Oosterveld, M., Suciu, S., Muus, P., Germing, U., Delforge, M., Belhabri, A., Aul, C., Selleslag, D., Ferrant, A., Marie, J.P., Amadori, S., Jehn, U., Mandelli, F., Hess, U., Hellstrom-Lindberg, E., Cakmak-Wollgast, S., Vignetti, M., Labar, B., Willemze, R., Witte, T.J. de, Oosterveld, M., Suciu, S., Muus, P., Germing, U., Delforge, M., Belhabri, A., Aul, C., Selleslag, D., Ferrant, A., Marie, J.P., Amadori, S., Jehn, U., Mandelli, F., Hess, U., Hellstrom-Lindberg, E., Cakmak-Wollgast, S., Vignetti, M., Labar, B., Willemze, R., and Witte, T.J. de

Abstract

Item does not contain fulltext, High-risk myelodysplastic syndrome (MDS) patients have usually a less favorable outcome after intensive treatment compared with de novo acute myeloid leukemia (AML) patients. This may reflect different disease-related and patient-related factors. The purpose of this analysis is to identify disease-specific prognostic factors and to develop prognostic scores for both patient groups. A total of 692 patients in the EORTC/GIMEMA AML-10 study and 289 patients in the CRIANT study received identical remission-induction and consolidation treatment. Estimated 5-year survival rate was 34 % in the AML-10 versus 27 % in the CRIANT study, and estimated disease-free survival was 40 % versus 28 %, respectively. In multivariate analysis, cytogenetic characteristics, white blood count, and age appeared prognostic for survival in both studies. French-American-British (FAB) subtype and performance status were prognostic in the AML-10 study only, whereas number of cytopenias and duration of antecedent hematologic disorder >6 months were prognostic in the CRIANT study only. The prognostic scores distinguish three groups with a 5-year survival rate of 54, 38, and 19 % in the AML-10 study versus 69, 37, and 5 % in the CRIANT study. The prognostic value of these scores has been validated on two external series. The new scoring systems form a practical tool to predict the outcome of individual MDS and AML patients treated with intensive antileukemic therapy.

Published
2015

160. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes

Author

Caocci, G, Voso, Mt, Angelucci, E, Stauder, R, Cottone, F, Abel, G, Nguyen, K, Platzbecker, U, Beyne Rauzy, O, Gaidano, G, Invernizzi, R, Molica, S, Criscuolo, Marianna, Breccia, M, Lübbert, M, Sanpaolo, G, Buccisano, F, Ricco, A, Palumbo, Ga, Niscola, P, Zhang, H, Fenu, S, La Nasa, G, Mandelli, F, Efficace, F., Caocci, G, Voso, Mt, Angelucci, E, Stauder, R, Cottone, F, Abel, G, Nguyen, K, Platzbecker, U, Beyne Rauzy, O, Gaidano, G, Invernizzi, R, Molica, S, Criscuolo, Marianna, Breccia, M, Lübbert, M, Sanpaolo, G, Buccisano, F, Ricco, A, Palumbo, Ga, Niscola, P, Zhang, H, Fenu, S, La Nasa, G, Mandelli, F, and Efficace, F.

Abstract

Higher-risk myelodysplastic syndromes (MDS) are rarely curable and have a poor prognosis. We investigated the accuracy of physicians' perception of patients' health status and the patients' preferences for involvement in treatment decisions. We examined 280 newly diagnosed higher-risk elderly MDS patients paired with their physicians. Survey tools included the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the Control Preference Scale. Overall concordance was 49% for physician perception of patient preferences for involvement in treatment decisions. In 36.4% of comparisons there were minor differences and in 14.6% there were major differences. In 44.7% of the patients preferring a passive role, physicians perceived them as preferring an active or collaborative role. Absence of the patient's request for prognostic information (P=0.001) and judging the patient as having a poor health status (P=0.036) were factors independently associated with the physicians' attitude toward a lower degree of patient involvement in clinical decisions. Agreement on health status was found in 27.5% of cases. Physicians most frequently tended to overestimate health status of patients who reported low-level health status. The value of decision aid-tools in the challenging setting of higher-risk MDS should be investigated to further promote patient-centered care.

Published
2015

161. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.

Author

Efficace, F, Gaidano, G, Breccia, M, Criscuolo, Marianna, Cottone, F, Caocci, G, Bowen, D, Lubbert, M, Angelucci, E, Stauder, R, Selleslag, D, Platzbecker, U, Sanpaolo, G, Jonasova, A, Buccisano, F, Specchia, G, Palumbo, G. A, Niscola, P, Wan, C, Zhang, H, Fenu, S, Klimek, V, Beyne Rauzy, O, Nguyen, K, Mandelli, F., Efficace, F, Gaidano, G, Breccia, M, Criscuolo, Marianna, Cottone, F, Caocci, G, Bowen, D, Lubbert, M, Angelucci, E, Stauder, R, Selleslag, D, Platzbecker, U, Sanpaolo, G, Jonasova, A, Buccisano, F, Specchia, G, Palumbo, G. A, Niscola, P, Wan, C, Zhang, H, Fenu, S, Klimek, V, Beyne Rauzy, O, Nguyen, K, and Mandelli, F.

Abstract

The primary objective of this study was to investigate factors associated with fatigue severity in newly diagnosed patients with higher-risk myelodysplastic syndromes (MDS). The secondary objectives were to assess symptom prevalence and to examine the relationships between fatigue, quality of life (QoL) and overall symptom burden in these patients. The analyses were conducted in 280 higher-risk MDS patients. Pre-treatment patient-reported fatigue was evaluated with the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale and QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Female gender (P = 0·018), poor performance status (i.e., ECOG of 2-4) (P < 0·001) and lower levels of haemoglobin (Hb) (P = 0·026) were independently associated with higher fatigue severity. The three most prevalent symptoms were as follows: fatigue (92%), dyspnoea (63%) and pain (55%). Patients with higher levels of fatigue also had greater overall symptom burdens. The mean global QoL scores of patients with the highest versus those with the lowest levels of fatigue were 29·2 [standard deviation (SD), 18·3] and 69·0 (SD, 18·8), respectively and this difference was four times the magnitude of a clinically meaningful difference. Patient-reported fatigue severity revealed the effects of disease burden on overall QoL more accurately than did degree of anaemia. Special attention should be given to the female patients in the management of fatigue.

Published
2015

162. PEG INTRON IN ESSENTIAL THROMBOCYTHAEMIA: TWO YEARS TREATAMENT EVALUTATION

Author

GUGLIOTTA L., BULGARELLI S., VIANELLI N., R.U.S.S.O.D., GAMBERI B., CANDONI A., MICHELUTTI T., IMOVILLI A., RUPOLI S., BARULLI S., TASSETTI A., LATAGLIATA R., FRATTARELLI N., SACCHI S., MONTANINI A., MAMMI C., CIANCIA R., ZANCHINI A., ZUMAGLINI F., DE BIASI E., BUCALOSSI A., GENTILI S., MAZZOTTA S., TABILIO A., MARCOMIGNI L., PASSAMONTI F., MALABARBA L., MIGLINO M., VALALDO R., GROSSI A., BALESTRI F., CACCIOLA E., CACCIOLA R., PISAPIA G., POGLIANI E., BONIFAZI F., FANIN R., LEONI P., MANDELLI F., ROTOLI B., ZACCARIA A., LAURIA F., MARTELLI M., LAZZARINO M., GOBBI M., BOSI A., GIUSTOLISI R., MAZZA P., BONVINI L., PISARRA P., FINCATO G., BACCARANI M., MARTINELLI, VINCENZO, Gugliotta, L., Bulgarelli, S., Vianelli, N., R. U. S. S. O., D., Gamberi, B., Candoni, A., Michelutti, T., Imovilli, A., Rupoli, S., Barulli, S., Tassetti, A., Latagliata, R., Frattarelli, N., Sacchi, S., Montanini, A., Mammi, C., Martinelli, Vincenzo, Ciancia, R., Zanchini, A., Zumaglini, F., DE BIASI, E., Bucalossi, A., Gentili, S., Mazzotta, S., Tabilio, A., Marcomigni, L., Passamonti, F., Malabarba, L., Miglino, M., Valaldo, R., Grossi, A., Balestri, F., Cacciola, E., Cacciola, R., Pisapia, G., Pogliani, E., Bonifazi, F., Fanin, R., Leoni, P., Mandelli, F., Rotoli, B., Zaccaria, A., Lauria, F., Martelli, M., Lazzarino, M., Gobbi, M., Bosi, A., Giustolisi, R., Mazza, P., Bonvini, L., Pisarra, P., Fincato, G., and Baccarani, M.

Abstract

Comunicazione orale Haemathologica, (abstract) vol 88 (suppl) n.ro 15

Published
2003

163. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study

Author

Mauro, Fr, Zinzani, P, Zaja, Francesco, Gentile, M, Vegna, Ml, Stefoni, V, Marin, L, Fanin, Renato, Baccarani, M, Tura, S, Mandelli, F., Mauro, Fr, Zinzani, P, Zaja, Francesco, Gentile, M, Vegna, Ml, Stefoni, V, Marin, L, Fanin, Renato, Baccarani, M, Tura, S, and Mandelli, F.

Subjects
Adult, Male, alpha-interferon, treatment, Remission Induction, fludarabine, Interferon-alpha, Neoplasms, Second Primary, Middle Aged, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Survival Analysis, Drug Administration Schedule, Treatment Outcome, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Humans, Prednisone, chronic lymphocytic leukemia, Female, Life Tables, chronic lymphocytic leukemia, treatment, fludarabine, alpha-interferon, Vidarabine, Aged
Abstract

BACKGROUND AND OBJECTIVES: Fludarabine is an effective therapy for patients with chronic lymphocytic leukemia (CLL) and interferon-alpha (IFN-alpha) has been reported to have anti-leukemic activity in CLL patients. A randomized study was designed to evaluate whether the addition of IFN-alpha to a first-line treatment with fludarabine and prednisone could increase the response rate in patients with advanced CLL and whether IFN-alpha given as maintenance therapy could improve the duration of response. DESIGN AND METHODS: One hundred and thirty-three patients were randomized to receive fludarabine (25 mg/m2/i.v., days 9-13) and prednisone (20 mg/m2, days 1, 3, 5, 7 and 14 and 40 mg/m2, days 9-13) (arm A: 66 patients) or in addition to the same schedule, IFN-alpha (2 MUI/sc, days 1, 3, 5, 7, 9, 11, 13 and 15) (arm B: 67 patients). Seventy-eight patients responsive to therapy entered the post-remission phase of the study in which 41 patients were randomized to receive IFN-alpha (3 MUI three times a week) and 37 to clinical observation. RESULTS: A similar response rate (complete responses + partial responses) was observed in the 2 arms: 86% for arm A and 84% for arm B (p = 0.4). A longer response duration was observed in patients who achieved a complete response (p = 0.001) and in patients who received maintenance therapy with IFN-alpha (p < 0.05). However, the quality of response was the only significant and independent factor influencing response duration (p < 0.01). No benefits in terms of infection-related mortality and morbidity could be ascribed to IFN-alpha administration. INTERPRETATION AND CONCLUSIONS: In previously untreated CLL patients with advanced disease a high response rate is obtained from first-line fludarabine and prednisone and no benefit is derived from the addition of IFN-alpha to this regimen. The achievement of a good quality response to therapy was the only independent predictor of a prolonged response.

Published
2003

164. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

Author

SUCIU S., MANDELLI F., DE WITTE T., ZITTOUN R., GALLO E., LABAR B., BELHABRI A., GIUSTOLISI R., DELARUE R., LISO V., BOURHIS J.H., DE ROSA, GENNARO, Suciu, S., Mandelli, F., DE WITTE, T., Zittoun, R., Gallo, E., Labar, B., DE ROSA, Gennaro, Belhabri, A., Giustolisi, R., Delarue, R., Liso, V., and Bourhis, J. H.

Published
2003

165. Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia

Author

PANE, FABRIZIO, IZZO, BARBARA, Camera A., Cimino G., Vitale A., Specchia G., Saglio G., Foa R., Salvatore F., Rotoli B., Mandelli F., QUINTARELLI, CONCETTA, Pane, Fabrizio, Izzo, Barbara, Quintarelli, Concetta, Camera, A., Cimino, G., Vitale, A., Specchia, G., Saglio, G., Foa, R., Salvatore, F., Rotoli, B., and Mandelli, F.

Published
2003

171. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

Author

Gupta, V, Richards, S, Rowe, J, Büchner, T, Hiddemann, W, Sauerland, C, Amadori, S, Rondelli, R, Testi, Am, Attal, M, Jourdan, E, Reiffers, J, Howman, A, Patel, S, Jacobs, P, Lee, S, Brunet, S, Sierra, J, Alonzo, T, Aplenc, R, Sung, L, Cutler, C, Sun, Z, Tallman, M, Ljungman, P, Labar, B, Willemze, R, Suciu, S, Collette, S, Dombret, H, Thomas, X, Ifrah, N, Hunault-Berger, M, Mandelli, F, Vignetti, M, Tsimberidou, Am, Pagnano, K, da Souza CA, Miranda, Ec, Diaz de Heredia, C, Ortega, Jj, Cornelissen, Jj, van der Holt, B, Oh, H, Takeuchi, J, Kaizer, H, Björkholm, M, Rosenborg, A, Keating, M, Zander, A, Fielding, A, Goldstone, A, Moorman, Av, Bassan, R, Ravindranath, Y, Weinstein, H, Oriol, A, Ribera, Jm, Powles, R, Appelbaum, F, Baker, Luigi, Coltman, C, Crowley, J, Kopecky, K, Messner, H, Akan, H, Beksac, M, Hills, R, Buck, G, Davies, K, Elphinstone, T, Evans, V, Gettins, L, Gregory, C, James, S, Mackinnon, L, Mchugh, T, Morris, P, Wade, R, and Wheatley, K.

Subjects
Oncology, Homologous, Adult, medicine.medical_specialty, Adolescent, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Child, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Randomized Controlled Trials as Topic, Transplantation, Autologous, Transplantation, Homologous, Young Adult, Hematology, Biochemistry, Cell Biology, Immunology, medicine.medical_treatment, Hematopoietic stem cell transplantation, law.invention, Randomized controlled trial, law, Acute lymphocytic leukemia, Internal medicine, 80 and over, Medicine, Young adult, Chemotherapy, Transplantation, Lymphoid Neoplasia, business.industry, Absolute risk reduction, medicine.disease, Surgery, Adult Acute Lymphoblastic Leukemia, business, Autologous
Abstract

Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains controversial. There are no randomized trials of allogeneic HCT. In the present study, updated individual patient data were collected and analyzed from studies with information on availability of matched sibling donor (used to mimic randomization) and from randomized trials of autograft versus chemotherapy. Data from 13 studies including 2962 patients, excluding Philadelphia chromosome–positive patients, showed a survival benefit for having a matched sibling donor for patients < 35 years of age (OR = 0.79; 95% CI, 0.70-0.90, P = .0003) but not for those ≥ 35 years of age (OR = 1.01; 95% CI, 0.85-1.19, P = .9; heterogeneity P = .03) because of the higher absolute risk of nonrelapse mortality for older patients. No differences were seen by risk group. There was a trend toward inferior survival for autograft versus chemotherapy (OR = 1.18; 95% CI, 0.99-1.41; P = .06). No beneficial effect of autografting was seen compared with chemotherapy in this analysis. We conclude that matched sibling donor myeloablative HCT improves survival only for younger patients, with an absolute benefit of approximately 10% at 5 years. Improved chemotherapy outcomes and reduced nonrelapse mortality associated with allogeneic HCT may change the relative effects of these treatments in the future.

Published
2013

172. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial

Author

Keating, S., Suciu, S., Witte, T.J.M. de, Mandelli, F., Willemze, R., Resegotti, L., Broccia, G., Thaler, J., Labar, B., Damasio, E., Bizzi, B., Rotoli, B., Vekhoff, A., Muus, P., Petti, M.C., Dardenne, M., Solbu, G., Vegna, M.L., and Zittoun, R.

Subjects
clonal remission after intensive antileukemic therapy (Biomed-2 1995) [European evaluation of intensive antileukemic therapy for patients with myelodysplastic syndrome (MDS) CRIANT]
Abstract

Contains fulltext : 22795___.PDF (Publisher’s version ) (Open Access)

Published
1996

174. A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group

Author

TESTI AM, DEL GIUDICE I, ARCESE W, MOLETI ML, GIONA F, BASSO G, BIONDI A, CONTER V, MESSINA C, RONDELLI R, MICOZZI A, MICALIZZI C, BARISONE E, LOCATELLI F, DINI G, ARICO M, COMIS M, LADOGANA S, LIPPI A, MURA R, PINTA MF, SANTORO N, VALSECCHI MG, MASERA G, MANDELLI F, AIEOP COOPERATIVE GROUP, CASALE, Fiorina, Testi, Am, DEL GIUDICE, I, Arcese, W, Moleti, Ml, Giona, F, Basso, G, Biondi, A, Conter, V, Messina, C, Rondelli, R, Micozzi, A, Micalizzi, C, Barisone, E, Locatelli, F, Dini, G, Arico, M, Casale, Fiorina, Comis, M, Ladogana, S, Lippi, A, Mura, R, Pinta, Mf, Santoro, N, Valsecchi, Mg, Masera, G, Mandelli, F, AIEOP COOPERATIVE, Group, Testi, A, Del Giudice, I, Moleti, M, Aricò, M, Casale, F, Pinta, M, and Valsecchi, M

Subjects
Male, Antineoplastic Combined Chemotherapy Protocol, Adolescent, Cytarabine, Hematopoietic Stem Cell Transplantation, Infant, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Disease-Free Survival, Follow-Up Studie, Survival Rate, Recurrence, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Preschool, Child, Idarubicin, Follow-Up Studies, Settore MED/15 - Malattie del Sangue, Human
Abstract

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complete remission; eight (8%) died during induction and 11 (11%) failed to respond. A total of 42 out of the 80 responders (52.5%) received a SCT: 19 from an identical sibling, 11 from a matched unrelated donor and 12 from umbilical cord blood cells. The estimated 4-year overall survival and event-free survival were 25% and 21% respectively. Disease-free survival at 4 years was 25.8% for the 80 responders. At 4 years, 39 out of 100 children remain alive, with 27 of them free of leukaemia. This induction therapy has shown antileukaemic efficacy with acceptable toxicity; moreover, all responders proved eligible for intensive consolidation.

Published
2002

176. FOLLOW UP A LUNGO TERMINE DEI PAZIENTI CON LMC-PH+ IN RISPOSTA CITOGENETICA COMPLETA CON TERAPIA INCLUDENTE INTERFERONE NELL’ERA IMATINIB - PROTOCOLLO GIMEMA CML0509

Author

Russo, D, Alimena, G, Colombi, C, Breccia, M, Soverini, S, Iacobucci, I, Cattina, F, Martinelli, G, Testoni, N, Liberati, Am, Appolloni, V, Tiribelli, M, Fanin, R, Ferrara, F, Annunziata, M, Trabacchi, E, Vallisa, D, De Vivo, A, Castagnetti, F, Fogli, M, Durante, S, Di Raimondo, F, Stagno, F, Carella, Am, Pica, G, Cortelezzi, A, Iurlo, A, Pregno, P, Vitolo, U, Abruzzese, E, De Fabritiis, P, Longinotti, M, Pardini, S, Musolino, C, Russo, S, Gobbi, M, Pierri, I, Gaidano, G, Lunghi, M, Visani, G, Barulli, S, Cazzola, M, Merante, S, Skert, C, Malagola, M, Rosti, G, Mandelli, F, and Baccarani, M

Published
2012

177. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?

Author

Efficace, F. Breccia, M. Saussele, S. Kossak-Roth, U. Cardoni, A. Caocci, G. Chie, W. Naeem, A. Nicolatou-Galitis, O. Cocks, K. Vignetti, M. Baccarani, M. Mandelli, F. Sprangers, M.

Subjects
hemic and lymphatic diseases, education
Abstract

The objective of this study was to investigate the health-related quality of life (HRQOL) aspects valued the most by patients with chronic myeloid leukemia (CML) receiving targeted therapies (TT), and to compare their perception with that of health-care professionals' (HCPs). Semi-structured interviews were conducted with 137 CML patients receiving TT from five different countries. An additional sample of 99 CML patients, completing an online interview, was considered for supportive analyses. A sample of 59 HCPs from 12 countries also participated in the study. Patients and HCPs were asked to rate and rank the importance of a predefined list of 74 HRQOL aspects of potential relevance for CML patients. Patients and HCPs agreed that the following five aspects are most important: fatigue, muscle cramps, swelling, worries, and uncertainty about health condition in the future, and importance of social support in coping with the disease. However, the difference in rankings between the two groups was substantial with respect to other HRQOL aspects investigated. Patients valued some issues related to symptoms much higher than HCPs, thus suggesting that a better symptom management could be the crucial aspects to improve HRQOL of CML patients.© 2012 Springer-Verlag.

Published
2012

178. Grapevine performance and production strategies in tropical climates

Author

CAMARGO, U. A., MANDELLI, F., CONCEIÇÃO, M. A. F., TONIETTO, J., UMBERTO ALMEIDA CAMARGO, CNPUV (APOSENTADO), FRANCISCO MANDELLI, CNPUV (APOSENTADO), MARCO ANTONIO FONSECA CONCEICAO, CNPUV, and JORGE TONIETTO, CNPUV.

Subjects
Vinho tropical, Vinho, Uva, Gerenciamento, Viticultura, Produção, Planejamento, Clima, Região tropical, Uva de mesa, Suco, Pomar
Abstract

Made available in DSpace on 2013-04-25T23:34:30Z (GMT). No. of bitstreams: 1 Grapevineperformanceandproductionstrategiesintropicalclimates.pdf: 304335 bytes, checksum: 1d734c257a115a593b255a6155498533 (MD5) Previous issue date: 2013-02-14

Published
2012

181. Involvement in treatment decisions, desire for prognostic information and quality of life in high-risk myelodysplastic syndromes: the physician's perspective

Author

Efficace, F, Alimena, G, Voso, Mt, Caocci, G, Di Tucci, A, Stauder, R, Sanpaolo, G, Gaidano, G, Breccia, M, Selleslag, D, Beyne-Rauzy, O, Wood, S, Ciceri, F, Specchia, G, Bowen, D, Buccisano, F, Deschler, B, Neuwirtova, R, Focan, C, Ackroyd, S, Criscuolo, M, Invernizzi, R, Ravoet, C, Paolini, R, Matta, G, Fenu, S, De Bock, R, Morra, E, Cottone, F, Vignetti, M, and Mandelli, F

Published
2011

182. Socio-demographic and clinical determinants of patient-reported symptom severity in chronic myeloid leukemia survivors in treatment with imatinib over the long run

Author

Efficace, F., Castagnetti, F., Breccia, M., Alimena, G., Cottone, F., Rosti, G., Lambertenghi Deliliers, G., Baratè, C., Russo Rossi, A., Fioritoni, G., Luciano, L., Turri, D., Nobile, F., Di Raimondo, F., Cavazzini, F., Bergamaschi, M., Leoni, P., Simula, M., Levato, L., Fava, Carmen, Pizzolo, G., Sica, S., Rambaldi, A., Pardini, S., Gherlinzoni, F., Salvucci, M., Tiribelli, M., Vignetti, M., and Mandelli, F.

Published
2011

184. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Author

Efficace, F, Baccarani, M, Breccia, M, Alimena, G, Rosti, G, Cottone, F, Deliliers, Gl, Baratè, C, Rossi, Ar, Fioritoni, G, Luciano, L, Turri, D, Martino, B, Di Raimondo, F, Dabusti, M, Bergamaschi, M, Leoni, P, Simula, Mp, Levato, L, Ulisciani, S, Veneri, Dino, Sica, S, Rambaldi, A, Vignetti, M, and Mandelli, F.

Subjects
QUALITY OF LIFE, CHRONIC MYELOID LEUCEMIA, TREATMENT
Published
2011

186. SOCIO-DEMOGRAPHIC AND CLINICAL DETERMINANTS OF PATIENT- REPORTED SYMPTOM SEVERITY IN CHRONIC MYELOID LEUKEMIA SURVIVORS IN TREATMENT WITH IMATINIB OVER THE LONG RUN

Author

Efficace, F, Castagnetti, F, Breccia, M, Alimena, G, Cottone, F, Rosti, G, Lambertenghi Deliliers, G, Baratè, C, Russo Rossi, A, Fioritoni, G, Luciano, L, Turri, D, Nobile, F, Di Raimondo, F, Cavazzini, F, Bergamaschi, M, Leoni, P, Simula, M, Levato, L, Fava, C, Pizzolo, G, Sica, S, Rambaldi, A, Pardini, S, Gherlinzoni, F, Salvucci, M, Tiribelli, M, Vignetti, M, and Mandelli, F

Published
2011

187. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?

Author

Zinzani PL, Martelli M, Magagnoli M, ZAJA, Francesco, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S., Zinzani, Pl, Martelli, M, Magagnoli, M, Zaja, Francesco, Storti, S, Pavone, E, Lauta, Vm, De Renzo, A, Gobbi, M, Bocchia, M, Ronconi, F, Scaramucci, L, Gherlinzoni, F, Palombi, F, Bendandi, M, Stefoni, V, Anticoli Borza, P, Cellini, C, Mandelli, F, and Tura, S.

Subjects
Adult, Male, Salvage Therapy, Adolescent, Lymphoma, Non-Hodgkin, Cytarabine, Leucovorin, Middle Aged, Disease-Free Survival, Bleomycin, Methotrexate, Treatment Outcome, Doxorubicin, Vincristine, Antineoplastic Combined Chemotherapy Protocols, Humans, Prednisone, Female, Fluorouracil, Cyclophosphamide, Retrospective Studies
Abstract

BACKGROUND AND OBJECTIVE: To examine the long-term clinical course and prognostic factors of patients with advanced aggressive non-Hodgkin's lymphoma (NHL) treated with third-generation regimens as front-line chemotherapy. DESIGN AND METHODS: A total of 348 patients aged

Published
1999

188. Will Molecular Biology Contribute to Refine Prognosis and to Select Treatment?

Author

Zaccaria, A, Martinelli, G, Buzzi, M, Farabegoli, P, Saglio, G, Guerrasio, A, Bernabei, P, Santini, V, Pellicci, P, Mencarelli, A, Coco, F, Diverio, D, Rambaldi, A, Santoro, A, Tura, S, Russo, D, Zuffa, E, Fanin, R, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Maiolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Danieli, G, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Liberati, A, Grignani, F, Tabilio, A, Martelli, M, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, Ascari, E, Risso, M, Damasio, E, Martino, S, Pardini, S, Longinotti, M, Miraglia, E, Debiase, R, Nardelli, S, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Prossomariti, L, Cimino, R, Derosa, C, Gabbas, A, Francesco, S, Gallamini, A, Difrancesco, A, Quaglino, D, Musolino, C, Squadrito, G, Avanzini, P, Gobbi, F, Nuova, A, Emilia, R, Aglietta, M, Camaschella, C, Mazza, M, Guglielmo, P, Cacciola, E, and Monaco, M

Subjects
INTERFERON, CHRONIC MYELOID LEUKEMIA, Cancer Research, PROGNOSIS, biology, Settore MED/06 - Oncologia Medica, business.industry, MOLECULAR BIOLOGY, Breakpoint, Transcript analysis, Hematology, HindIII, Bioinformatics, Restriction site, Text mining, Oncology, Risk index, biology.protein, Medicine, In patient, business, Settore MED/15 - Malattie del Sangue, Southern blot
Abstract

The possible prognostic value of the position of the breakpoint within the M-BCR in patients with Phl+ CML is still being debated. We analyzed the DNA rearrangements and the transcript types of 244 patients and tried to correlate the data obtained with prognostic features, defined according to Sokal's risk index, and with chronic phase and/or survival duration. The exact location of the breakpoint, either 5' or 3' to the Hind III restriction site within the M-BCR was identified. Moreover, the exact M-BCR subregion was also identified. As a whole, 150 pts were rearranged in the 5' part and 94 in the 3' part of the M-BCR. No correlation was observed between the site of rearrangement on the one hand and the Sokal's prognostic index and survival, on the other. Transcript analysis was performed in 130 patients; 59 carried an a2b2 and 69 an a2b3 pattern. Two patients carried both transcripts. Of the patients rearranged in the 5' area, according to Southern blotting, 29.2% showed an a2b3 transcript. Therefore, R...

Published
1993

189. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

Author

Efficace, F., primary, Rosti, G., additional, Breccia, M., additional, Cottone, F., additional, Giesinger, J. M., additional, Stagno, F., additional, Iurlo, A., additional, Russo Rossi, A., additional, Luciano, L., additional, Martino, B., additional, Galimberti, S., additional, Turri, D., additional, Bergamaschi, M., additional, Tiribelli, M., additional, Fava, C., additional, Angelucci, E., additional, Mandelli, F., additional, and Baccarani, M., additional

Published
2015
Full Text
View/download PDF

192. A SIMPLE CLINICAL PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKAEMIA PATIENTS WITH NORMAL KARYOTYPE: A RETROSPECTIVE ANALYSIS ON 530 CASES

Author

Malagola, Michele, Skert, C, Vignetti, M, Piciocchi, A, Martinelli, G, Clavio, M, Gobbi, M, Candoni, A, Damiani, D, Bocchia, M, Lauria, F, Zaccaria, A, Mazza, P, Visani, G, Peli, A, Mancini, M, Foà, R, Martelli, M, Cantore, N, Caraci, Mr, Petrini, M, De Fabritiis, P, Fioritoni, G, Nobile, F, Fabbiano, F, Pastore, D, Specchia, G, Baccarani, M, Lo Coco, F, Amadori, S, Mandelli, F, and Russo, Domenico

Published
2010

193. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

Author

Willemze, R., Suciu, S., Meloni, G., Labar, B., Marie, J.P., Halkes, C.J., Muus, P., Mistrik, M., Amadori, S., Specchia, G., Fabbiano, F., Nobile, F., Sborgia, M., Camera, A., Selleslag, D.L., Lefrere, F., Sr., Magro, D., Sica, S., Cantore, N., Beksac, M., Berneman, Z., Thomas, X., Melillo, L., Guimaraes, J.E., Leoni, P., Luppi, M., Mitra, M.E., Bron, D., Fillet, G., Marijt, E.W., Venditti, A., Hagemeijer, A., Mancini, M., Jansen, J.H., Cilloni, D., Meert, L., Fazi, P., Vignetti, M., Trisolini, S.M., Mandelli, F., Witte, T.J. de, Willemze, R., Suciu, S., Meloni, G., Labar, B., Marie, J.P., Halkes, C.J., Muus, P., Mistrik, M., Amadori, S., Specchia, G., Fabbiano, F., Nobile, F., Sborgia, M., Camera, A., Selleslag, D.L., Lefrere, F., Sr., Magro, D., Sica, S., Cantore, N., Beksac, M., Berneman, Z., Thomas, X., Melillo, L., Guimaraes, J.E., Leoni, P., Luppi, M., Mitra, M.E., Bron, D., Fillet, G., Marijt, E.W., Venditti, A., Hagemeijer, A., Mancini, M., Jansen, J.H., Cilloni, D., Meert, L., Fazi, P., Vignetti, M., Trisolini, S.M., Mandelli, F., and Witte, T.J. de

Abstract

Item does not contain fulltext, PURPOSE: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine. PATIENTS AND METHODS: The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) in 1,942 newly diagnosed patients with AML, age 15 to 60 years, comparing remission induction treatment containing daunorubicin, etoposide, and either standard-dose (SD) cytarabine (100 mg/m(2) per day by continuous infusion for 10 days) or high-dose (HD) cytarabine (3,000 mg/m(2) every 12 hours by 3-hour infusion on days 1, 3, 5, and 7). Patients in complete remission (CR) received a single consolidation cycle containing daunorubicin and intermediate-dose cytarabine (500 mg/m(2) every 12 hours for 6 days). Subsequently, a stem-cell transplantation was planned. The primary end point was survival. RESULTS: At a median follow-up of 6 years, overall survival was 38.7% for patients randomly assigned to SD cytarabine and 42.5% for those randomly assigned to HD cytarabine (log-rank test P = .06; multivariable analysis P = .009). For patients younger than age 46 years, survival was 43.3% and 51.9%, respectively (P = .009; multivariable analysis P = .003), and for patients age 46 to 60 years, survival was 33.9% and 32.9%, respectively (P = .91). CR rates were 72.0% and 78.7%, respectively (P < .001) and were 75.6% and 82.4% for patients younger than age 46 years (P = .01) and 68.3% and 74.8% for patients age 46 years and older (P = .03). Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation, or with sec

Published
2014

194. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes

Author

Efficace, F, Mandelli, F, Avvisati, G, Cottone, F, Ferrara, F, Di Bona, E, Specchia, G, Breccia, M, Levis, A, Sica, Simona, Finizio, O, Kropp, Mg, Fioritoni, G, Cerqui, E, Vignetti, M, Amadori, S, Schlenk, Rf, Platzbecker, U, Lo Coco, F., Sica, Simona (ORCID:0000-0003-2426-3465), Efficace, F, Mandelli, F, Avvisati, G, Cottone, F, Ferrara, F, Di Bona, E, Specchia, G, Breccia, M, Levis, A, Sica, Simona, Finizio, O, Kropp, Mg, Fioritoni, G, Cerqui, E, Vignetti, M, Amadori, S, Schlenk, Rf, Platzbecker, U, Lo Coco, F., and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

A randomized clinical trial compared efficacy and toxicity of standard all-trans-retinoic acid (ATRA) plus chemotherapy versus ATRA plus arsenic trioxide in patients with newly diagnosed, low- or intermediate-risk acute promyelocytic leukemia (APL). Here, we report health-related quality-of-life (HRQOL) results.

Published
2014

195. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

Author

Willemze, R, Suciu, S, Meloni, G, Labar, B, Marie, J, Halkes, Cjm, Muus, P, Mistrik, M, Amadori, S, Specchia, G, Fabbiano, F, Nobile, F, Sborgia, M, Camera, A, Selleslag, Dld, Lefrère, F, Magro, D, Sica, Simona, Cantore, N, Beksac, M, Berneman, Z, Thomas, X, Melillo, L, Guimaraes, Je, Leoni, P, Luppi, M, Mitra, Me, Bron, D, Fillet, G, Marijt, Ewa, Venditti, A, Hagemeijer, A, Mancini, M, Jansen, J, Cilloni, D, Meert, L, Fazi, P, Vignetti, M, Trisolini, Sm, Mandelli, F, De Witte, T., Sica, Simona (ORCID:0000-0003-2426-3465), Willemze, R, Suciu, S, Meloni, G, Labar, B, Marie, J, Halkes, Cjm, Muus, P, Mistrik, M, Amadori, S, Specchia, G, Fabbiano, F, Nobile, F, Sborgia, M, Camera, A, Selleslag, Dld, Lefrère, F, Magro, D, Sica, Simona, Cantore, N, Beksac, M, Berneman, Z, Thomas, X, Melillo, L, Guimaraes, Je, Leoni, P, Luppi, M, Mitra, Me, Bron, D, Fillet, G, Marijt, Ewa, Venditti, A, Hagemeijer, A, Mancini, M, Jansen, J, Cilloni, D, Meert, L, Fazi, P, Vignetti, M, Trisolini, Sm, Mandelli, F, De Witte, T., and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.

Published
2014

196. Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes

Author

Efficace, F, Gaidano, G, Sprangers, M, Cottone, F, Breccia, M, Voso, Maria Teresa, Caocci, G, Stauder, R, Di Tucci, Aa, Sanpaolo, G, Selleslag, D, Angelucci, E, Platzbecker, U, Mandelli, F., Efficace, F, Gaidano, G, Sprangers, M, Cottone, F, Breccia, M, Voso, Maria Teresa, Caocci, G, Stauder, R, Di Tucci, Aa, Sanpaolo, G, Selleslag, D, Angelucci, E, Platzbecker, U, and Mandelli, F.

Abstract

The main objective of this study was to assess preferences for involvement in treatment decisions and requests for prognostic information in newly diagnosed higher-risk myelodysplastic syndrome (MDS) patients.

Published
2014

197. The Role of Interferon-α in the Management of Myelomatosis

Author

Mandelli F and Avvisati G

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Salvage treatment, Alpha interferon, Hematology, Immunotherapy, medicine.disease, Cytokine, Internal medicine, Immunopathology, Interferon α, Immunology, Medicine, business, Multiple myeloma, Interferon alfa, medicine.drug
Abstract

This article reviews the therapeutic efficacy of α-interferon (α-IFN) in the management of myelomatosis. Four major therapeutic uses of α-IFN in myelomatosis are reviewed: 1) The use of α-IFN alone as induction treatment of previously untreated multiple myeloma patients; 2) the association of α-IFN to conventional induction therapies; 3) the use of α-IFN as salvage treatment for multiple myeloma; and 4) the use of α-IFN as maintenance treatment for multiple myeloma patients responding to conventional chemotherapies. Published data indicate that a better control of multiple myeloma is obtained by combining (during the induction treatment) α-IFN to conventional chemotherapies and adding, once a plateau phase has been achieved, a continuous maintenance treatment of α-IFN.

Published
1992

198. A videira e o tempo na Serra Gaúcha: orientações aos viticultores considerando o prognóstico climático para abril-maio

Author

MANDELLI, F. and FRANCISCO MANDELLI, CNPUV.

Subjects
Rio Grande do Sul, Uva, Região da Serra Gaúcha, Viticultura, Meteorologia, Clima, Prognóstico climático
Abstract

De acordo com o prognóstico climático**, baseado nas tendências oceânicas, especialmente os padrões associados às anomalias positivas de temperaturas da superfície do mar nas regiões subtropicais do Atlântico e do Pacífico, espera-se condições atmosféricas que favoreçam o aumento de chuvas em abril e maio. O prognóstico mostra que a precipitação em abril, em relação ao padrão cIimatológico, será um pouco acima do padrão, especialmente no Oeste do Estado; para maio, a tendência mostra precipitação pouco acima em todas as regiões. O padrão cIimatológico de chuva para a região da Serra Gaúcha (dados de Bento Gonçalves) nos meses de abril e maio é, respectivamente, de 114 e 107 milímetros.

Published
2009

200. A videira e o tempo na Serra Gaúcha: orientações aos viticultores considerando o prognóstico climático para junho-julho

Author

MANDELLI, F. and FRANCISCO MANDELLI, CNPUV.

Subjects
Rio Grande do Sul, Uva, Viticultura, Região da Serra, Meteorologia, Clima, Previsão
Abstract

Orientações aos viticultores considerando o prognóstico climático para junho-julho. De acordo com o- prognóstico climático**, esperam-se condições atmosféricas próximas ao padrão climatológico para o Rio Grande do Sul para o período junho/agosto. No entanto, a chuva pode ficar um pouco abaixo da média no Estado, em junho e julho. O padrão climatológico de chuva para a região da Serra Gaúcha (dados de Bento Gonçalves) nos meses de junho e julho é, respectivamente, 157 e 161 milímetros. A tendência de ocorrer

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results